ARTICLEhttps://harbor.dev.pubfactory.com/view/journals/jnccn/15/8/article-p983.xmlNeoadjuvant Treatment With Trastuzumab and FOLFOX Induces a Complete Pathologic Response in a Metastatic ERBB2 (HER2)-Amplified Duodenal Cancer2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/15/8/article-p983.pdf2026-04-18Neoadjuvant Treatment With Trastuzumab and FOLFOX Induces a Complete Pathologic Response in a Metastatic ERBB2 (HER2)-Amplified Duodenal Cancerhttps://harbor.dev.pubfactory.com/view/journals/jnccn/15/8/article-pxxxv.xmlOncology Research Program2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/15/8/article-pxxxv.pdf2026-04-18Oncology Research Programhttps://harbor.dev.pubfactory.com/view/journals/jnccn/15/8/article-pxxvii.xmlNCCN News2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/15/8/article-pxxvii.pdf2026-04-18NCCN Newshttps://harbor.dev.pubfactory.com/view/journals/jnccn/15/8/article-p978.xmlTargeted MAPK Pathway Inhibitors in Patients With Disseminated Pilocytic Astrocytomas2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/15/8/article-p978.pdf2026-04-18Targeted MAPK Pathway Inhibitors in Patients With Disseminated Pilocytic Astrocytomashttps://harbor.dev.pubfactory.com/view/journals/jnccn/15/8/article-p973.xmlWhen It's Really Good, We Know It!2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/15/8/article-p973.pdf2026-04-18When It's Really Good, We Know It!https://harbor.dev.pubfactory.com/view/journals/jnccn/15/8/article-p975.xmlTo the Editor: How Do We Solve This Confusion?2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/15/8/article-p975.pdf2026-04-18To the Editor: How Do We Solve This Confusion?https://harbor.dev.pubfactory.com/view/journals/jnccn/15/8/article-p1022.xmlShort- and Long-Term Survival in Metastatic Pancreatic Adenocarcinoma, 1993–20132026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/15/8/article-p1022.pdf2026-04-18Short- and Long-Term Survival in Metastatic Pancreatic Adenocarcinoma, 1993–2013https://harbor.dev.pubfactory.com/view/journals/jnccn/15/8/article-p989.xmlNCCN Guidelines Insights: Palliative Care, Version 2.20172026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/15/8/article-p989.pdf2026-04-18NCCN Guidelines Insights: Palliative Care, Version 2.2017https://harbor.dev.pubfactory.com/view/journals/jnccn/15/8/article-p998.xmlRace- and Sex-Based Disparities in the Therapy and Outcomes of Squamous Cell Carcinoma of the Anus2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/15/8/article-p998.pdf2026-04-18Race- and Sex-Based Disparities in the Therapy and Outcomes of Squamous Cell Carcinoma of the Anushttps://harbor.dev.pubfactory.com/view/journals/jnccn/15/8/article-p1005.xmlThe Evolution of Metastatic Colorectal Cancer Clinical Trials: Application of the ASCO Framework for Assessing Value2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/15/8/article-p1005.pdf2026-04-18The Evolution of Metastatic Colorectal Cancer Clinical Trials: Application of the ASCO Framework for Assessing Valuehttps://harbor.dev.pubfactory.com/view/journals/jnccn/15/8/article-p1015.xmlCosts and Benefits of Extended Endocrine Strategies for Premenopausal Breast Cancer2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/15/8/article-p1015.pdf2026-04-18Costs and Benefits of Extended Endocrine Strategies for Premenopausal Breast Cancerhttps://harbor.dev.pubfactory.com/view/journals/jnccn/15/8/article-p1028.xmlPancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/15/8/article-p1028.pdf2026-04-18Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncologyhttps://harbor.dev.pubfactory.com/view/journals/jnccn/15/8/article-p1078.xmlActing on Rare Driver Alterations: Is Getting a Meaningful Response a Game of Chance or Scientific Rigor?2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/15/8/article-p1078.pdf2026-04-18Acting on Rare Driver Alterations: Is Getting a Meaningful Response a Game of Chance or Scientific Rigor?https://harbor.dev.pubfactory.com/view/journals/jnccn/15/8/article-p1063.xmlDNA Repair Dysfunction in Pancreatic Cancer: A Clinically Relevant Subtype for Drug Development2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/15/8/article-p1063.pdf2026-04-18DNA Repair Dysfunction in Pancreatic Cancer: A Clinically Relevant Subtype for Drug Developmenthttps://harbor.dev.pubfactory.com/view/journals/jnccn/15/8/article-p1070.xmlTrends in Neoadjuvant Approaches in Pancreatic Cancer2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/15/8/article-p1070.pdf2026-04-18Trends in Neoadjuvant Approaches in Pancreatic Cancer